U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Nasdaq GlobeNewswire, 14 Apr 2015
Accessed on 21 Apr 2015 from http://globenewswire.com/news-release/2015/04/14/724357/10128835/en/U-S-Patent-Office-Declares-an-Interference-Between-Forward-Pharma-and-Biogen-Regarding-the-Treatment-of-Multiple-Sclerosis-With-480-mg-Daily-Dose-of-DMF-the-Active-Ingredient-in-Te.html.